Compare
Lipocine Inc. vs Dianthus Therapeutics, Inc. vs Korsana Biosciences, Inc. vs Rani Therapeutics Holdings, Inc.
| Latest fiscal year | Lipocine Inc. LPCN | Dianthus Therapeutics, Inc. DNTH | Korsana Biosciences, Inc. KRSA | Rani Therapeutics Holdings, Inc. RANI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.98M | $2.04M | $2.07M | $1.63M |
| Revenue growth (YoY) | -82.3% | -67.3% | +3.7% | +58.9% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -524.7% | n/m | -239.8% | n/m |
| Net margin | -487.1% | n/m | -170.1% | n/m |
| Net income | -$9.63M | -$162.34M | -$3.53M | -$40.95M |
| EPS (Diluted) | -$1.69 | -$4.20 | -$1.11 | -$0.45 |
| Operating cash flow | -$9.76M | -$129.06M | -$3.31M | -$18.71M |
| Free cash flow | n/a | n/a | n/a | -$18.80M |
| Cash & equivalents | $5.21M | $51.09M | $3.24M | $18.62M |
| Total assets | $17.01M | $530.92M | $9.98M | $58.62M |
| Total liabilities | $2.53M | $37.52M | n/a | $17.11M |
| Shareholders' equity | $14.48M | $493.40M | $9.09M | $33.01M |
| Return on year-end equity | -66.5% | -32.9% | -38.8% | -124.1% |
| Shares outstanding | 6.16M | 43.22M | 3.82M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Lipocine Inc. | Dianthus Therapeutics, Inc. | Korsana Biosciences, Inc. | Rani Therapeutics Holdings, Inc. |
|---|---|---|---|---|
| Latest | $1.98M Ended 2025-12-31 | $2.04M Ended 2025-12-31 | $2.07M Ended 2025-12-31 | $1.63M Ended 2025-12-31 |
| 1 year earlier | $11.20M Ended 2024-12-31 | $6.24M Ended 2024-12-31 | $2.00M Ended 2024-12-31 | $1.03M Ended 2024-12-31 |
| 2 years earlier | -$2.85M Ended 2023-12-31 | $2.83M Ended 2023-12-31 | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $500.0K Ended 2022-12-31 | n/a | $297.0K Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $16.14M Ended 2021-12-31 | n/a | $3.94M Ended 2021-12-31 | $2.72M Ended 2021-12-31 |